

## Ministry of Health Ministère de la Santé

OHIP, Pharmaceuticals and Division de l'Assurance-santé, des produits pharmaceutiques et des

Devices Division appareils et accessoires fonctionnels

Delivery and Eligibility Review Branch Direction de la prestation des programmes et de l'examen de l'admissibilité

3<sup>rd</sup> Floor, 5700 Yonge Street 5700, rue Yonge, 3<sup>e</sup> étage Toronto ON M2M 4K5 Toronto ON M2M 4K5

Telephone: (416) 327-8109 Téléphone : (416) 327-8109 1 866 811-9893 Toll Free: 1-866-811-9893 Sans frais: Facsimile: (416) 327-8912 Télécopieur: (416) 327-8912 1-866-598-6530 Toll Free Sans frais: 1 866 598-6530

<u>www.ontario.ca/health</u> <u>www.ontario.ca/sante</u>

## Dear Health Care Provider:

## RE: Revised start date of 2022-2023 Season for Respiratory Syncytial Virus (RSV) Prophylaxis for High-Risk Infants Program

The Ministry of Health has been monitoring RSV hospital admission rates and RSV positivity throughout Ontario as the traditional RSV season approaches. Based on current data projections, an early onset of the RSV season is anticipated in some regions of the province

Following consultation with the RSV Advisory Group, I am writing to inform you that the 2022-2023 RSV season will officially start on **October 31**, **2022** for those sites experiencing high levels of RSV activity. Sites experiencing low levels of RSV activity can begin prophylaxis on **November 7**, **2022**.

Traditionally the RSV season has been considered ongoing when there are two or more local RSV-related hospitalizations per week for two consecutive weeks. The current trends for this season appear to suggest a mix of active and non-active regions throughout the province. Therefore, the ministry has made the decision to allow the season to start earlier in <u>all</u> regions of Ontario.

While the official start date of the RSV season has been changed to October 31, 2022 for those sites experiencing an early start to the season, RSV clinics are not required to start administering palivizumab as of that date. Each clinic and RSV site should weigh the logistical and administrative requirements necessary to begin the season on the specified dates in combination with the current trends and RSV activity in their region.

There will be no change to the criteria for RSV prophylaxis eligibility due to the change in season start date. The current RSV criteria for this season can be found on the ministry's RSV website. Note that age-related criteria will be calculated as if the season began on November 1, 2022. As a reminder, the definition of  $\leq$  6 months as stated in the RSV criteria implies that an eligible infant born on May 1, 2022 or thereafter would be considered less than or equal to 6 months of age for that season.

Please note that the RSV season end date remains April 1, 2023. The ministry and its expert Advisory Group will continue to monitor the data throughout the season and will announce any changes to the season end date based on the best data as it becomes available.

The ministry's expert Advisory Group is recommending that the general dosing schedule remain the same as in previous years. The dosing schedule is as follows:

- Dose number one to be given at week 0
- Dose number two to be given 21 days after the first dose
- o Further doses to be given in 28-day intervals

The maximum number of doses allowed this season will be set to a maximum of 5 doses. Additional doses can only be administered following approval by the Ministry of Health.

Sites may wish to place new orders or confirm existing orders to ensure they receive supply in time for any appointments they may have booked. As a reminder, palivizumab can only be administered to an infant who has been approved for funding. Clinics and RSV sites should refrain from booking appointments and administering palivizumab until they have confirmed an eligible infant has been approved for funding.

I trust that this information will be helpful in delivering this Program efficiently and effectively through the RSV season.

Sincerely,

Original signed by

David Schachow Director, Delivery and Eligibility Review Branch